patrick de Zeeuw

We rescue lonely motorcycles

[patrick de Zeeuw @patrick_dezeeuw]

@StockSavvyShay I went long Amazon when they delivered 2 tubes of honda bond in the same day

[Humacyte @humacyte]

Major Milestone in Biotech Options for the U.S. Military

Humacyte has officially made its first sale of Symvess™, a bioengineered human vessel, to a U.S. Military Treatment Facility—marking a breakthrough in patient care for service members and veterans. Following FDA approval and ECAT listing, Symvess is now available across 35 military hospitals and 160 VA facilities.

This is more than a sale - it's a step toward transforming how we treat vascular trauma.

Read the full press release here: https://t.co/JucSMvQux0

Trademarks are property of Humacyte Global, Inc
© 2025 Humacyte Global Inc. All Rights Reserved.

#Biotech #RegenerativeMedicine #MilitaryHealth #Humacyte #Symvess #FDAApproved #InnovationInCare #VeteransHealth #HealthcareBreakthrough

[James DePorre @RevShark]

$HUMA Humacyte Announces First Symvess™ Sale to Military Treatment Facility

https://t.co/yN8h8fH53p

[Will @medtechmd]

$HUMA Announces First Symvess™ Sale to Military Treatment Facility.

“We are excited to see the first purchase and use of Symvess by a military treatment facility,” said Dr. Laura Niklason, President and CEO of Humacyte, Inc”. https://t.co/sPdmnYJ5nS

[patrick de Zeeuw @patrick_dezeeuw]

@JVMonte2 Locked Down by Dr John and Blues in Orbit by Duke Ellington

[Humacyte @humacyte]

Humacyte has just announced that Symvess™  has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, which makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilities.

For more details, please read the full press release here: https://t.co/Ab1zA1VBBG

#Humacyte #HealthcareInnovation #Bioengineering #Biotech

[James DePorre @RevShark]

$HUMA showing up on the radar today

[Will @medtechmd]

$HUMA CFO Dale Sander acquires shares on the open market 4/10/25.

[patrick de Zeeuw @patrick_dezeeuw]

@dampedspring Yes

[Humacyte @humacyte]

🏅 Humacyte is thrilled to announce the first units sold of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma. This marks a pivotal step forward in our mission to enhance patient care.

In addition, since our commercial launch a few short weeks ago, the sales team and our healthcare partners have demonstrated the significant importance of this new product technology through the growing number of Value Analysis Committees currently under review.

⭐ In a breakthrough effort, 36 Value Analysis Committee submissions have been achieved. These committee meetings focus on discussing the need of new, beneficial products that impact patient care. This ensures healthcare practitioners are evaluating the need and impact of a product before putting this in their inventory. We are proud to support these numerous requests and to serve the real need for innovation in the trauma space.

🥇 Symvess is the first and only approved bioengineered vessel for patients needing urgent extremity arterial repair, offering a universally implantable, off-the-shelf solution. Clinical data supports strong performance in patency, low infection, and low amputation rates.

👏 Join us in celebrating this milestone and the new phase in patient care!
See the full press release to read more details: https://t.co/BMSw1WgnKU

Contact our Team to Learn More: https://t.co/KVIoRgmfpO

SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING at https://t.co/Eg2XmrWjCQ
See Full Important Safety Information at https://t.co/tmU7ZF2DS1

INDICATION: SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. Warnings and Precautions: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. Adverse Reactions: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

© 2025 Humacyte Global Inc. All Rights Reserved. US-SYM-000197
#Humacyte #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

[patrick de Zeeuw @patrick_dezeeuw]

@dampedspring I own it because of you.

[patrick de Zeeuw @patrick_dezeeuw]

@RevShark Projecting 101

[patrick de Zeeuw @patrick_dezeeuw]

@LyleLovett WOT!!!

[patrick de Zeeuw @patrick_dezeeuw]

@dampedspring Thank you!

[patrick de Zeeuw @patrick_dezeeuw]

@20th_Centurygal Selena Gomez with my daughter. 5000 screaming little girls are louder the Iron Maiden.

[Humacyte @humacyte]

Thank you for taking the time to learn more about Humacyte’s FDA Approved, Symvess™, Acellular Tissue Engineered Vessel (ATEV™), this past weekend at SCCACS. As this is a first-in-class, universally implantable, bioengineered human vessel, it was exciting to share this new, lifesaving technology with you.

The discussions were educational for us, and we hope they were for you as well. We appreciated everyone's enthusiasm to learn more. We look forward to continuing the conversations!

Learn more about Symvess here: https://t.co/1f77QQzSoV

See the Prescribing Information, including Boxed Warning: https://t.co/Eg2XmrWRso

#Humacyte #SCCACS2025 #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA @AmCollSurgeons

[James DePorre @RevShark]

Updated $HUMA Investor Presentation

https://t.co/EybyKxHtr7

[James DePorre @RevShark]

$HUMA update.
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma.
DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced an update of plans for the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Humacyte is responding to requests for quotations from hospitals and has initiated the Value Analysis Committee approval processes at multiple hospitals as part of the preparation for market launch.

The U.S. Food and Drug Administration (FDA) granted a full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible. Shortly after approval, Humacyte provided the final packaging and product batch release information required for FDA review prior to shipment of product. Humacyte currently expects to have authorization to commence product shipment early this quarter and continues to build product supply to support market launch.

Humacyte has recruited and trained a highly experienced sales team for the commercial launch of Symvess. All ten sales team members are multi-year President’s Club winners, representing the top 10% of achievers in their prior sales organizations. All sales team members have demonstrated consistent overachievement with average hospital medical device and biotech experience exceeding 15 years. Each sales team member has experience in vascular surgery and/or trauma surgery, and 80% have previous experience selling regenerative therapies. All team members have experience selling clinically differentiated disruptive technologies and premium priced portfolios.

Humacyte announced that the price of Symvess will be $29,500 per unit. The Company has developed a Budget Impact Model based on the clinical results supporting the approval of Symvess, and the estimated reduction in clinical complications potentially achievable by treating specific patients with Symvess versus current standard of care. Based on the model, the per-patient cost of treating patients with Symvess is estimated to be less than the cost of treating trauma patients with synthetic grafts, cryopreserved allografts, or xenografts. Major drivers of cost savings associated with Symvess were attributed to reductions in the rate of amputation and vascular conduit infection.

Additionally, Humacyte submitted an NTAP (New Technology Add-On Payment) application for Symvess to CMS in October 2024. Humacyte presented the Symvess data at a public Town Hall with the Centers for Medicare and Medicaid Services (CMS) on December 11, 2024. If successful, NTAP reimbursement will start for discharges on October 1, 2025, offering hospitals additional payment to cover a portion of the costs associated with Symvess.

“We are very excited to take the major steps in providing healthcare providers a novel alternative for treating patients suffering from extremity arterial injury,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “We are pleased to see interest from multiple hospitals and to have commenced the Value Analysis Committee approval processes. We look forward to the anticipated publication of our Budget Impact Model which highlights the major drivers of cost savings associated with Symvess and complement our strong clinical results.”

Symvess, or the ATEV™ (acellular tissue engineered vessel), is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. While harvesting vein from a trauma patient takes valuable surgical time and is not always feasible due to damage to veins or to the limbs, Symvess is available off-the-shelf, and does not require further injuring the patient to obtain vascular repair material. Humacyte’s BLA included positive results from the V005 pivotal Phase 2/3 clinical study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds, and industrial accidents. It was utilized by vascular and trauma surgeons in Level 1 Trauma centers throughout the U.S. and Israel to repair severe limb-threatening and life-threatening injuries, and in front-line hospitals in Ukraine to treat wartime injuries. Results from these studies were published in JAMA Surgery on November 20, 2024. In the civilian and military clinical studies, Symvess was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.

[patrick de Zeeuw @patrick_dezeeuw]

@JVMonte2 Phil Keaggy

[James DePorre @RevShark]

Why would you believe any $HUMA bear that was wrong about FDA approval?